Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

MDX-1342

One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.

Trial Locations (24)

10032

Columbia University Medical Center, New York

16635

Altoona Center for Clinical Research, Duncansville

21239

Good Samaritan Hospital and Johns Hopkins Hospital, Baltimore

32127

Coastal Medical Research, Inc, Port Orange

33334

Centre for Rheumatology, Immunology and Arthritis (CRIA), Fort Lauderdale

34233

Lovelace Scientific Resources, Venice

48910

Justus Fiechtner, Lansing

50924

klinikum der Universitat zu Koln, Cologne

61115

Kharkiv Medical Academy of Postgraduate Education, City Clinical General Hospital #25, Kharkiv

69035

Zaporizhya State Medical University, City Clinical Hopsital #6, Therapeutics Department, Zaporizhya

69600

Zaporizhzhya Regional Clinical Hospital, Rheumatology Department, Zaporizhzhya

81675

Klinikum rechts der Isar der TU Munchen, Munich

83045

V.K. Gusak Institute of Urgent & Reconstructive Surgery under UAMS, Hospital Therapy and Rehabilitaiton Clinic, Donetsk

85381

Sun Valley Arthritis Center LTD., Peoria

90036

Impact Clinical Trials, Los Angeles

98405

George Krick, MD, Tacoma

99204

Arthritis Northwest Rheumatology, PLLC, Spokane

01307

"Universitatsklinikum Carl Gustav Carus an der Technischen Universtitat Dresden", Dresden

H-8230

DRC Gyógyszervizsgáló Központ Kft, Balatonfüred

H-1083

Semmelweis Egyetem Altalanos Orvostudomanyi Kar-I. sz, Budapest

H-4012

DEOEC Kinikai Farmakologiai Tanszek, Debrecen

Unknown

First Department of Medicine, Szeged

The Kellgren Centre for Rheumatology, Manchester

SO16 6YD

Welcome Trust Clinical Research Facility, Southampton General Hospital, Southampton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00639834 - Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter